Cantor Fitzgerald Reiterates Overweight on Intra-Cellular Therapies, Maintains $90 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Intra-Cellular Therapies (NASDAQ:ITCI) and maintained a $90 price target.
June 23, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Intra-Cellular Therapies (NASDAQ:ITCI) and maintained a $90 price target.
The reiteration of an Overweight rating by Cantor Fitzgerald analyst Charles Duncan indicates a positive outlook for Intra-Cellular Therapies. The maintained $90 price target suggests potential upside for the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100